[
    [
        {
            "time": "2018-03-15",
            "original_text": "This Just In: Goldman Sachs Picks 4 Big Pharma Stocks to Buy",
            "features": {
                "keywords": [
                    "Goldman Sachs",
                    "Big Pharma",
                    "Stocks to Buy"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "This Just In: Goldman Sachs Picks 4 Big Pharma Stocks to Buy",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 4,
                "Market_Scope": 6,
                "Time_Proximity": 9,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        },
        {
            "time": "2018-04-01",
            "original_text": "British Columbia to be first Canadian province to switch patients to biosimilars",
            "features": {
                "keywords": [
                    "British Columbia",
                    "Canadian",
                    "biosimilars"
                ],
                "sentiment_score": 0.6,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "British Columbia to be first Canadian province to switch patients to biosimilars",
                "Correlation": 5,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 7,
                "Entity_Density": 3,
                "Market_Scope": 7,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-05-10",
            "original_text": "See what the IHS Markit Score report has to say about Eli Lilly and Co.",
            "features": {
                "keywords": [
                    "IHS Markit Score",
                    "Eli Lilly",
                    "report"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "See what the IHS Markit Score report has to say about Eli Lilly and Co.",
                "Correlation": 6,
                "Sentiment": 5,
                "Importance": 5,
                "Impact": 4,
                "Duration": 4,
                "Entity_Density": 7,
                "Market_Scope": 4,
                "Time_Proximity": 5,
                "Headline_Structure": 5,
                "Source_Recency": 5
            }
        },
        {
            "time": "2018-06-20",
            "original_text": "Lilly Announces Licensing Agreement for Non-Opioid Pain Asset from Centrexion Therapeutics",
            "features": {
                "keywords": [
                    "Lilly",
                    "Licensing Agreement",
                    "Non-Opioid Pain",
                    "Centrexion Therapeutics"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Lilly Announces Licensing Agreement for Non-Opioid Pain Asset from Centrexion Therapeutics",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 3,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        }
    ]
]